CWP
AMRX icon

Concord Wealth Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Concord Wealth Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-600
Closed -$3.64K – 849
2024
Q1 		$3.64K Buy
+600
New +$3.38K ﹤0.01% 692

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concord Wealth Partners's AMRX Position: Q2 2024 in Review

Concord Wealth Partners sold out of Amneal Pharmaceuticals (AMRX) in Q2 2024, closing a stake of 600 shares — an estimated $3.64K sold.

Concord Wealth Partners first reported a position in AMRX in Q1 2024 and held it in 1 quarter. The position peaked at $3.64K in Q1 2024. 181 funds tracked by Wall St. Rank hold AMRX as of Q2 2024.

  • Concord Wealth Partners reported no remaining Amneal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Concord Wealth Partners sold 600 Amneal Pharmaceuticals shares in Q2 2024, an estimated $3.64K.
  • Concord Wealth Partners first reported a position in Amneal Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Concord Wealth Partners's Amneal Pharmaceuticals position peaked at $3.64K in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2024.

Based on Concord Wealth Partners's 13F filing for Q2 2024, filed 31 Jul 2024.